secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2023-04-26T23:59:59+00:00
Accession:  0001048477-23-000016
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin Q1 revenue $596.4M (+15% YoY); VOXZOGO guidance raised to $380-$430M
-----------------------------------------------------------------------------

- GAAP diluted EPS $0.27 (down from $0.63 due to $89M prior-year PRV gain); Non-GAAP EPS $0.60 (up from $0.52).
- VOXZOGO Q1 revenue $87.8M (+346% YoY); full-year guidance raised from $330-$380M to $380-$430M, driven by Japan and Brazil.
- ROCTAVIAN full-year revenue guidance lowered to $50-$150M (from $100-$200M) due to Germany reimbursement shift and U.S. PDUFA delay to June 30, 2023.
- Enzyme product revenues $448.1M (+5% YoY); ALDURAZYME up 41% on timing of orders to Sanofi.
- Total cash & investments $1,492.7M; full-year revenue guidance unchanged at $2.375-$2.5B, with GAAP net income $155-$205M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847723000016/0001048477-23-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847723000016/bmrn-20230426.htm
  HTML page:      https://secwatch.observer/filing/0001048477-23-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer